A new study provides more evidence that GLP-1 RAs don’t raise the risk for pancreatic cancer and may in fact offer some protection.

With brand-name GLP-1s for obesity treatment on and off the shortage list, prescribing can get complicated. Five providers ...

There have been a slew of studies recently supporting the notion that the same mechanisms that help folks lose weight ...

There's a new player in the running game, and it's not the latest carbon-plated shoe or fancy GPS watch. GLP-1 medications ...

In an analysis of more than 7,000 stroke survivors, those who were taking either a GLP1-receptor agonist or an SGLT2 ...

chronic kidney disease and a history of heart attack or a history of heart failure. Within the entire study period, the death rate among stroke survivors who took either a GLP-1 or an SGLT2 was 11.8%, ...

It’s hard to remember a time before Ozempic, Wegovy, and other injectable drugs referred to as GLP-1 receptor agonists (that ...

GLP-1 Receptor Agonist medications, such as Ozempic, combined with exercise and nutrition, can help reduce obesity, according ...

GLP-1 receptor agonists and SGLT2 inhibitors, two classes of medications most commonly prescribed to treat Type 2 diabetes or ...

New research presented at the ACG Annual Meeting suggests that GLP-1RAs lower the risk of pancreatic cancer in patients with ...

For patients with type 2 diabetes mellitus (T2DM), glucagon-like peptide 1 receptor agonist (GLP-1 RA) use is associated with ...

HERSHEY, PA. — GLP-1 weight-loss drugs are having a “mild impact” on The Hershey Co.’s business, president and chief executive officer Michele Buck told analysts in a conference call on fiscal 2024 ...